Laura Buisson, OD
Optometrist · Thibodaux, LANPI 1760796577
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 275 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Among optometrist clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $27.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson Vision Care, Inc.$1K
- Alcon$774
- Oyster Point Pharma, Inc.$732
- Dompe US, Inc.$516
- Tarsus Pharmaceuticals, Inc.$452
- plus $3K from 17 others
What the payments were for
- Food & beverage$7,37798%
- Entertainment$1592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 33 | $1,140 |
| Johnson & Johnson Vision Care, Inc. | 35 | $1,077 |
| Alcon | 57 | $774 |
| Oyster Point Pharma, Inc. | 29 | $732 |
| Dompe US, Inc. | 8 | $516 |
| Tarsus Pharmaceuticals, Inc. | 20 | $452 |
| Harrow Eye, LLC | 13 | $379 |
| Sun Pharmaceutical Industries Inc. | 18 | $378 |
| Novartis | 24 | $317 |
| Optos, Inc. | 2 | $296 |
| Carl Zeiss Meditec USA, Inc. | 2 | $279 |
| Shire North American Group Inc | 5 | $235 |
| Coopervision Inc. | 8 | $229 |
| Bausch & Lomb Americas Inc. | 9 | $188 |
| Glaukos Corporation | 2 | $182 |
| Kala Pharmaceuticals, Inc. | 2 | $118 |
| Apellis Pharmaceuticals, Inc. | 1 | $93 |
| Aerie Pharmaceuticals, Inc. | 2 | $36 |
| Ocular Therapeutix, Inc. | 1 | $29 |
| Astellas Pharma US Inc | 1 | $27 |
| Sight Sciences, Inc. | 1 | $23 |
| Biotissue Holdings Inc. | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Acuvue$514
- Oxervate$368
- PANORAMIC OPHTHALMOSCOPE$317
- OCT OPHTHALMOSCOPE$317
- VUITY$242
- XDEMVY$228
- iDose$172
- NFC-700$159
- CIRRUS HD-OCT$147
- P200DTx$137
- P200T$137
- P200TE$137
- P200TxE$137
- RESTASIS MULTIDOSE$134
- CLARUS$132
- XIIDRA$123
- VEVYE$119
- Clariti Contact Lens$118
- LUMIGAN$107
- TYRVAYA$106
How this compares
$7,535 in reported general payments places this provider in the 95th percentile of 500 optometrist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 324 | $264,368 |
| XiidraLifitegrast | 73 | $64,360 |
| XdemvyLotilaner | 23 | $44,768 |
| VevyeCyclosporine | 50 | $40,664 |
| LumiganBimatoprost | 67 | $35,454 |
| CequaCyclosporine | 33 | $25,314 |
| TyrvayaVarenicline Tartrate | 38 | $25,091 |
| CombiganBrimonidine Tartrate/Timolol | 67 | $24,007 |
| EysuvisLoteprednol Etabonate | 29 | $17,020 |
| RocklatanNetarsudil Mesylat/Latanoprost | 32 | $14,020 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 52 | $13,753 |
| Latanoprost | 684 | $7,553 |
| Travoprost | 47 | $6,259 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 44 | $5,645 |
| Cyclosporine | 17 | $3,608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,140 | $323,829458 claims |
| Bausch & Lomb Americas Inc.Xiidra | $188 | $64,36073 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $452 | $44,76823 claims |
| Harrow Eye, LLCVevye | $379 | $40,66450 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $378 | $25,31433 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $732 | $25,09138 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $118 | $17,02029 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $36 | $14,02032 claims |
| AlconSimbrinza | $774 | $13,75352 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 500 optometrist providers in Louisiana.
Other optometrist in Thibodaux
- Jenaye DerocheThibodaux$5K
- David MitchellThibodaux$5K
- Pamela TheriotShreveport$207K
- Joshua DavidsonGonzales$189K
- Jeffrey WilhiteMarrero$86K
- Christopher WrotenHammond$59K
- James LamarNew Orleans$45K
- John McCallLogansport$32K
- Robert KellyMarrero$26K
- Shane FontenotJennings$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.